Skip to main content

Table 2 Efficacy and safety profiles of modelled interventions

From: Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece

 

Metformina

Meformin + glimepiridea

Metformin + vildagliptina

Metformin + basal insulinb

Metformin + intensive insulinb

HbA1c initial absolute 1 year change

−1.03

−0.53

−0.44

−1.10

−1.10

Symptomatic Hypoglycaemia Risk (per year), %

0.00

16.20

1.66

16.20

16.20

Severe Hypoglycaemia Risk (per year), %

0.00

1.38

0.00

3.30

3.30

Weight gain (kg/year)

0.00

1.56

-0.23

1.70

1.70

  1. aSource: Ferrannini et al. [15]
  2. bSource: Monami et al. [21]